A recent publication from the WHO identifies that EU pharmaceutical drug prices are too high and that the process pharmaceutical companies use to determine price is too opaque.
We're thrilled to announce our participation at ISPOR Europe 2023 in Copenhagen this November. We'll...
We summarise the World Orphan Drug Congress Europe 2023 including keynote and panel sessions on EU H...
Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.
Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.